Table 4.

Adverse events by preferred term- multiple-dose study (Part 2).

	Anti-SARS-CoV-2 IgY
	2 mg TID	4 mg TID	8 mg TID	Placebo TID	All Participants
	(N=6)	(N=6)	(N=6)	(N=6)	(N=24)
	n (%) E	n (%) E	n (%) E	n (%) E	n (%) E
Participants with ≥1 TEAE	4 (66.7%) 7	2 (33.3%) 3	4 (66.7%) 5	4 (66.7%) 5	14 (58.3%) 20
MedDRA Preferred Term
Headache	0	0	3 (50.0%) 3	2 (33.3%) 2	5 (20.8%) 5
Upper respiratory tract infection	0	0	1 (16.7%) 1	1 (16.7%) 1	2 (8.3%) 2
Contusion	0	0	0	1 (16.7%) 1	1 (4.2%) 1
Dental discomfort	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Dizziness	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Ear pain	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Epistaxis	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Eyelid irritation	0	0	1 (16.7%) 1	0	1 (4.2%) 1
Injection site hematoma	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Nasal congestion	0	0	0	1 (16.7%) 1	1 (4.2%) 1
Parosmia	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Presyncope	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Rhinorrhea	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Skin abrasion	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Tenderness	1 (16.7%) 1	0	0	0	1 (4.2%) 1

E, number of events; n, number of participants; TEAE, treatment-emergent adverse event.